Diversifying the Pipeline of Product Concepts for an HIV Vaccine
2010-2011 RFP Overview (Closed as of April 1, 2011)
The Bill & Melinda Gates Foundation has made major investments in the development of an HIV vaccine. The Collaboration for AIDS Vaccine Discovery (CAVD), launched by the foundation in 2006, established a new model of collaboration and cooperation in HIV vaccine research. By supporting vaccine discovery consortia that are separately pursuing novel candidate vaccines but linked by a commitment to sharing of data and materials and supported by a common platform of centralized services, the CAVD enables the bold pursuit of novel vaccine concepts in a supportive and enabling environment. The focus of the CAVD has been on translational research, harnessing knowledge to develop new vaccine concepts and to advance the most promising of them to clinical trials.
The goal of this Request for Proposals (RFP) is to fortify our commitment to translational research, building on current successes while infusing even greater diversity into the pipeline of product concepts for HIV vaccines. As the CAVD evolves, we will measure success by how rapidly novel ideas and the latest scientific advances are captured as new product concepts, the efficiency with which a diverse portfolio of product concepts is explored, and the extent to which capacity to advance a range of products to clinical trials is ensured through the collective effort of major funders and implementers. While the foundation will continue to invest in innovative early discovery, support the development of advanced products, and invest in an enabling environment including centralized service facilities, this solicitation is focused solely on the diversification of the product concept pipeline, from product conceptualization to clinical trials at the stage of first-in-man.
The approaches under consideration for this call for applications include the following four topic areas:
Detailed information about the objectives, scope, eligibility criteria, and application process is provided in the following document “Diversifying the Pipeline of Product Concepts for an HIV Vaccine: RFP Overview and Guidelines.”